- Home
- REX vs PLRX Comparison
REX vs PLRX Comparison
Compare REX & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REX
- PLRX
- Stock Information
- Founded
- REX 1980
- PLRX 2015
- Country
- REX United States
- PLRX United States
- Employees
- REX N/A
- PLRX N/A
- Industry
- REX Major Chemicals
- PLRX Biotechnology: Pharmaceutical Preparations
- Sector
- REX Industrials
- PLRX Health Care
- Exchange
- REX Nasdaq
- PLRX Nasdaq
- Market Cap
- REX 699.5M
- PLRX 84.7M
- IPO Year
- REX N/A
- PLRX 2020
- Fundamental
- Price
- REX $52.76
- PLRX $1.29
- Analyst Decision
- REX Strong Buy
- PLRX Hold
- Analyst Count
- REX 1
- PLRX 10
- Target Price
- REX $50.00
- PLRX $9.79
- AVG Volume (30 Days)
- REX 135.4K
- PLRX 1.5M
- Earning Date
- REX 08-26-2025
- PLRX 08-06-2025
- Dividend Yield
- REX N/A
- PLRX N/A
- EPS Growth
- REX N/A
- PLRX N/A
- EPS
- REX 3.24
- PLRX N/A
- Revenue
- REX $639,600,000.00
- PLRX N/A
- Revenue This Year
- REX $3.27
- PLRX N/A
- Revenue Next Year
- REX $17.11
- PLRX N/A
- P/E Ratio
- REX $16.30
- PLRX N/A
- Revenue Growth
- REX N/A
- PLRX N/A
- 52 Week Low
- REX $33.45
- PLRX $1.10
- 52 Week High
- REX $52.77
- PLRX $16.10
- Technical
- Relative Strength Index (RSI)
- REX 75.75
- PLRX 43.30
- Support Level
- REX $48.32
- PLRX $1.13
- Resistance Level
- REX $50.10
- PLRX $1.43
- Average True Range (ATR)
- REX 1.51
- PLRX 0.11
- MACD
- REX 0.15
- PLRX -0.01
- Stochastic Oscillator
- REX 99.21
- PLRX 37.57
About REX REX American Resources Corporation
REX American Resources Corp operates as a holding company, which engages in investment in alternative energy and ethanol production entities. Its operating segments include Ethanol and By-Products. Its products include dried distillers grains, modified distillers grains, and non-food grade corn oil.
About PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.